Idorsia Ltd (19T.SG)
| Previous close | 19.80 |
| Open | 17.78 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.78 - 18.42 |
| 52-week range | 17.78 - 19.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIdorsia takes steps to address short-term liquidity needs
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of IdorsiaMain investors Jean-Paul and Martine Clozel fully support this requestFinancial status as of March 31, 2024, to be published on April 17, 2024, in conjunction with the invitation to the bondholder meetingPostponement of the Full Year 2023 and Q1 2024 Financial Results publication to May 21, 2
- GlobeNewswire
Idorsia thanks Guy Braunstein for his years of service as he retires
Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especia
- GlobeNewswire
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs.TRYVIO is the first oral anti-hypertensive therapy which works via a new therapeutic pathway to be approved in almost 40 years.Idorsia plans to make TRYVIO available to the millions of patients in the US who are not controlled on other drugs in t
